GlycoNex Inc. was founded in 2001. We have grown to be the pioneer in Taiwan that combines glycotechnologies and human monoclonal antibody technologies to develop cancer drugs. GlycoNex’s core business covers NBE and biosimilars development, antibody engineering, cell line development, glycan structure analysis, and antibody reagent for research use.
